F-18-Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography in the Follow-up of Breast Cancer With Elevated Levels of Tumor Markers

Haug, Alexander; Schmidt, Gerwin P.; Klingenstein, Annemarie; Heinemann, Volker; Stieber, P.; Priebe, Markus; Fougère, Christian la; Becker, Christoph; Hahn, Klaus; Tiling, Reinhold

doi:10.1097/01.rct.0000284394.83696.42

Cited by 47 publications

(54 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This presents a diagnostic challenge, often requiring some conventional diagnostic tests to localize the metastases or recurrent disease. Cases of asymptomatic patients with elevated tumour marker levels have demonstrated a high rate of falsenegatives with conventional morphological imaging modalities (Haug et al, 2007). In a review by Lamy et al (Lamy et al, 2005), the authors summarized the results of a set of some studies in colorectal, breast and ovarian cancer.…”

Section: A Summary Of Articles Concerning Pet and Pet/ct In Patients mentioning

confidence: 99%

“…PET/CT overcomes this problem and increases the diagnostic accuracy (with a gain of ~ 10% in diagnostic accuracy, Haug et al, 2007).…”

Section: Detection Of Recurrent Diseasementioning

confidence: 99%

“…Combining both morphological and functional imaging technologies in a single scanner can be expected to overcome the respective limitations of CT, MRI, and PET, and provide the additional advantage of simultaneous data acquisition, obviating the need for patient repositioning, and so on. Haug et al (Haug et al, 2007) studied patients with an isolated increase of tumour markers, who were asymptomatic but with suspected disease recurrence. Thirty-four patients were studied, five of whom were symptomatic and 29 asymptomatic.…”

Section: Pet Vs Pet/ct and Tumour Markersmentioning

confidence: 99%

“…However, FDG PET is not sensitive enough for the detection of micrometastases, yet it remains the most accurate imaging device for early breast cancer recurrence detection. In fact, although FDG PET cannot rule out microscopic disease, it nevertheless has particular value in providing a reliable assessment of the true extent of the disease in a single examination (Vranjesevic et al, 2002;Haug et al, 2007).…”

Section: Tumour Markers and Pet Alonementioning

confidence: 99%

See 3 more Smart Citations

Tumour Markers and Molecular Imaging with FDG PET/CT in Breast Cancer: Their Combination for Improving the Prediction of Disease Relapse

Evangelista¹,

Baretta²,

Vinante³

et al. 2012

Positron Emission Tomography - Current Clinical and Research Aspects

View full text Add to dashboard Cite

Section: A Summary Of Articles Concerning Pet and Pet/ct In Patients mentioning

confidence: 99%

“…PET/CT overcomes this problem and increases the diagnostic accuracy (with a gain of ~ 10% in diagnostic accuracy, Haug et al, 2007).…”

Section: Detection Of Recurrent Diseasementioning

confidence: 99%

Section: Pet Vs Pet/ct and Tumour Markersmentioning

confidence: 99%

Section: Tumour Markers and Pet Alonementioning

confidence: 99%

See 2 more Smart Citations

Tumour Markers and Molecular Imaging with FDG PET/CT in Breast Cancer: Their Combination for Improving the Prediction of Disease Relapse

Evangelista¹,

Baretta²,

Vinante³

et al. 2012

Positron Emission Tomography - Current Clinical and Research Aspects

View full text Add to dashboard Cite

“…FDG-PET/CT can evaluate the whole body (except the brain) in a single examination and is very useful for detecting recurrent or residual tumors because of its high sensitivity and specificity in comparison with conventional techniques. Table 3 shows the results of major studies that have evaluated the role of PET/CT [56][57][58][59][60][61][62][63][64][65][66][67][68][69]. We excluded studies in which staging and restaging populations were mixed.…”

Section: Restagingmentioning

confidence: 99%

Present and future role of FDG-PET/CT imaging in the management of breast cancer

Kitajima

Miyoshi

2016

Jpn J Radiol

View full text Add to dashboard Cite

by malignant cells, opened a new field in clinical oncologic imaging. Recently, integrated positron emission tomography/computed tomography (PET/CT), in which a full-ringdetector clinical PET scanner and multidetector-row helical CT scanner are combined, has made it possible to acquire both metabolic and anatomic imaging data using a single device in a single diagnostic session, and provides precise anatomic localization of suspicious areas of increased FDG uptake. When used in a clinical setting, FDG-PET/CT leads to a significant improvement in diagnostic accuracy and has had a considerable impact on patient management, including diagnosis, initial staging, optimization of treatment, restaging, monitoring of the response to therapy, and prognostication of various malignant tumors. We herein review the current and future roles of FDG-PET/CT in the management of breast cancer, discussing its usefulness and limitations for imaging in these patients. DiagnosisFDG-PET imaging has poor sensitivity (<50 %) for subcentimeter breast cancers [9,10]. This is due to the limited spatial resolution of PET and, in some cases, by tumor characteristics (e.g., low FDG avidity in grade 1 cancer, ductal carcinoma in situ, or lobular carcinoma) [1,2]. Specificity can also be altered by variations of FDG uptake in certain benign conditions, such as infection, fibroadenoma, ductal adenoma, inflammatory granulomatous mastitis, and fibrocystic changes [3].In order to improve specificity, some authors would obtain a second series of PET images centered on the breast approximately 2 h after FDG injection (dual-time imaging) [4]. Indeed, FDG uptake seems to increase with time in the case of malignancy, while some inflammatory lesions show stable or decreasing uptake [4]. However, dual-time Abstract Integrated positron emission tomography/computed tomography (PET/CT) with 2-[18F]fluoro-2-deoxyd-glucose (FDG) is a useful tool for acquisition of both glucose metabolic and anatomic imaging data using a single device in a single diagnostic session, and has opened a new field in clinical oncologic imaging. FDG-PET/CT has been used successfully for the diagnosis, initial staging, restaging, early treatment response assessment, evaluation of metastatic disease response, and prognostication of breast cancer as well as various malignant tumors. We herein review the current place and role of FDG-PET/CT in the management of breast cancer, focusing on its usefulness and limitations in the imaging of these patients.

show abstract

Breast cancer recurrence diagnosis suspected on tumor marker rising

Champion

Brain

Giraudet

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND: Breast cancer recurrence is often suspected on tumor marker rising in asymptomatic patients. The value of fluorine-18 fluorodeoxyglucose (18FDG)-positron emission tomography/computed tomography (PET/CT) imaging to detect recurrence and its subsequent impact on patient management were retrospectively assessed. METHODS: PET/CT scans were performed on 228 asymptomatic patients (mean, 60.8 years; range, 30-91 years) presenting with rising CA 15-3 and/or CEA serum levels. RESULTS: PET/CT scans were positive in 181 patients (79.5%) and normal in 47 patients, whereas 187 true recurrences were diagnosed. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of PET/CT imaging for detection of breast cancer recurrence were 93.6%, 85.4%, 96.7%, 74.5%, and 92.1%, respectively. When compared with the standard workup available in 67 patients, PET/CT imaging had a higher sensitivity and accuracy (94.5% vs 33% and 94% vs 48%, respectively). Recurrences were confirmed by pathology, conventional imaging techniques, or radiological and clinical follow-up beyond 1 year (mean, 34 months; range, 12-67 years) in 32, 130, and 25 patients, respectively. The diagnosis of recurrence led to a treatment modification in 123 patients (54%). CONCLUSIONS: 18FDG-PET/CT imaging is an efficient technique to detect breast cancer recurrence suspected on tumor marker rising in asymptomatic patients. It may thus contribute to improve patient management, providing an earlier diagnosis with complete whole-body staging as a ''one-stop shop'' procedure.

show abstract

F-18-Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography in the Follow-up of Breast Cancer With Elevated Levels of Tumor Markers

Abstract: The PET/CT is a valuable modality for the follow-up of patients with breast cancer and elevated levels of tumor markers.

Cited by 47 publications

References 27 publications

Tumour Markers and Molecular Imaging with FDG PET/CT in Breast Cancer: Their Combination for Improving the Prediction of Disease Relapse

Tumour Markers and Molecular Imaging with FDG PET/CT in Breast Cancer: Their Combination for Improving the Prediction of Disease Relapse

Present and future role of FDG-PET/CT imaging in the management of breast cancer

Breast cancer recurrence diagnosis suspected on tumor marker rising

Contact Info

Product

Resources

About